Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Participants needed: 2,000
Trial details
Age: 18-99Biological sex: AllType: ObservationalSponsor: German CLL Study GroupUpdated: Apr 30, 2026Locations: 2
Eligibility criteria

• Subjects must voluntarily sign and date an informed consent, ap-proved by an i... [+4]

• Patients without participation in one of the first-line studies of the GCLLSG... [+3]

Read more
Status: Recruiting

Registry of the German CLL Study Group

Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation

Participants needed: 8,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: German CLL Study GroupUpdated: Dec 8, 2025Locations: 1Duration: 25 Years
Eligibility criteria

Confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK-LGL, HCL or Richter's tra... [+6]

Patients without confirmed diagnosis of CLL, B-PLL, T-PLL, SLL, T or NK- LGL, HC... [+1]

Read more
Status: Recruiting

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

This multicenter, prospective, open-label, randomized, superiority phase 3 study is designed to demonstrate that treatment with a triple combination of acalabrutinib, obinutuzumab and venetoclax (GAVe) prolong the progression-free survival (PFS) as compared to treatment with the combination of obinutuzumab and venetoclax (GVe) in pa-tients with high risk CLL (defined as having at least one of the follow-ing risk factors: 17p-deletion, TP53-mutation, complex karyotype or an unmutated IGHV-gene status).

Participants needed: 202
Trial details
Phase: Phase 3Age: 18-120Biological sex: AllType: InterventionalSponsor: German CLL Study GroupUpdated: Aug 17, 2025Locations: 30
Eligibility criteria

Documented CLL/SLL requiring treatment according to iwCLL criteria [+9]

Any prior CLL-specific therapies (except corticosteroid treatment administered d... [+7]

Read more
Status: Recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

Participants needed: 83
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: German CLL Study GroupUpdated: Dec 30, 2024Locations: 11
Eligibility criteria

Confirmed diagnosis of CLL according to iwCLL criteria (Hallek et al, 2018) [+11]

Patients who did not respond to previous line of RT therapy (i.e. primary progre... [+29]

Read more